RxDoctor Payments DataLook up a doctor →

Sandeep Gupta, MD

Pulmonary Disease · Houston, TXNPI 1063500353

Payments from drug & device makers

$1,099,381in general payments, 2019–2025

Across 648 payments — averaging $1696.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$765K
  • AstraZeneca$129K
  • Johnson & Johnson$93K
  • Verona Pharma, Inc.$68K
  • GSK$22K
  • Insmed, Inc.$7K
  • plus $14K from 31 others

What the payments were for

  • Consulting fees$4,4034%
  • Speaking & faculty fees$95,12081%
  • Travel & lodging$7,5506%
  • Food & beverage$10,7799%
  • Education$2970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,099,381 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$232,221
Medicare patients
743
Services billed
2,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter356$384,270
OfevNintedanib Esylate24$321,119
Breo ElliptaFluticasone/Vilanterol116$74,312
Breztri AerosphereBudesonide/Glycopyr/Formoterol71$57,527
Combivent RespimatIpratropium/Albuterol Sulfate25$30,708
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$29,192
EliquisApixaban21$21,863
SymbicortBudesonide/Formoterol Fumarate26$12,989
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$11,855
Albuterol Sulfate HfaAlbuterol Sulfate219$6,531
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$5,886
Ventolin HfaAlbuterol Sulfate32$2,704
Wixela InhubFluticasone Propion/Salmeterol14$1,905
Azithromycin212$1,128
Prednisone177$719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$22,470$487,774510 claims
Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat$3,272$363,68261 claims
AstraZenecaBreztri Aerosphere, Symbicort$128,750$70,51697 claims
PfizerEliquis$71$21,86321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →